중도 및 중증 만성신장병(CKD) : 시장 인사이트, 역학, 시장 예측(2034년)

DelveInsight's "Moderate and Severe Chronic Kidney Disease (CKD) - Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of the Moderate and Severe Chronic Kidney Disease (CKD), historical and forecasted epidemiology as well as the Moderate and Severe Chronic Kidney Disease (CKD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Moderate and Severe Chronic Kidney Disease (CKD) market report provides current treatment practices, emerging drugs, Moderate and Severe Chronic Kidney Disease (CKD) market share of the individual therapies, current and forecasted Moderate and Severe Chronic Kidney Disease (CKD) market size from 2020 to 2034 segmented by seven major markets. The Report also covers current Moderate and Severe Chronic Kidney Disease (CKD) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered:

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2020-2034

Moderate and Severe Chronic Kidney Disease (CKD) Disease Understanding and Treatment Algorithm

The DelveInsight Moderate and Severe Chronic Kidney Disease (CKD) market report gives a thorough understanding of the Moderate and Severe Chronic Kidney Disease (CKD) by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.

Diagnosis

This segment of the report covers the detailed diagnostic methods or tests for Moderate and Severe Chronic Kidney Disease (CKD).

Treatment

It covers the details of conventional and current medical therapies available in the Moderate and Severe Chronic Kidney Disease (CKD) market for the treatment of the condition. It also provides Moderate and Severe Chronic Kidney Disease (CKD) treatment algorithms and guidelines in the United States, Europe, and Japan.

Moderate and Severe Chronic Kidney Disease (CKD) Epidemiology

The Moderate and Severe Chronic Kidney Disease (CKD) epidemiology division provide insights about historical and current Moderate and Severe Chronic Kidney Disease (CKD) patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Moderate and Severe Chronic Kidney Disease (CKD) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2020 to 2034.

Country Wise-Moderate and Severe Chronic Kidney Disease (CKD) Epidemiology

The epidemiology segment also provides the Moderate and Severe Chronic Kidney Disease (CKD) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Moderate and Severe Chronic Kidney Disease (CKD) Drug Chapters

Drug chapter segment of the Moderate and Severe Chronic Kidney Disease (CKD) report encloses the detailed analysis of Moderate and Severe Chronic Kidney Disease (CKD) marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Moderate and Severe Chronic Kidney Disease (CKD) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Drugs

The report provides the details of the marketed product available for Moderate and Severe Chronic Kidney Disease (CKD) treatment.

Moderate and Severe Chronic Kidney Disease (CKD) Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for Moderate and Severe Chronic Kidney Disease (CKD) treatment.

Moderate and Severe Chronic Kidney Disease (CKD) Market Outlook

The Moderate and Severe Chronic Kidney Disease (CKD) market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Moderate and Severe Chronic Kidney Disease (CKD) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of Moderate and Severe Chronic Kidney Disease (CKD) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, Moderate and Severe Chronic Kidney Disease (CKD) market in 7MM is expected to change in the study period 2020-2034.

Key Findings

This section includes a glimpse of the Moderate and Severe Chronic Kidney Disease (CKD) market in 7MM.

The United States Market Outlook

This section provides the total Moderate and Severe Chronic Kidney Disease (CKD) market size and market size by therapies in the United States.

EU-5 Countries: Market Outlook

The total Moderate and Severe Chronic Kidney Disease (CKD) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Market Outlook

The total Moderate and Severe Chronic Kidney Disease (CKD) market size and market size by therapies in Japan is also mentioned.

Moderate and Severe Chronic Kidney Disease (CKD) Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Moderate and Severe Chronic Kidney Disease (CKD) market or expected to get launched in the market during the study period 2020-2034. The analysis covers Moderate and Severe Chronic Kidney Disease (CKD) market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Moderate and Severe Chronic Kidney Disease (CKD) Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Moderate and Severe Chronic Kidney Disease (CKD) key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Moderate and Severe Chronic Kidney Disease (CKD) emerging therapies.

Reimbursement Scenario in Moderate and Severe Chronic Kidney Disease (CKD)

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current market trends, we take KOLs and SME's opinion working in Moderate and Severe Chronic Kidney Disease (CKD) domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Moderate and Severe Chronic Kidney Disease (CKD) market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Moderate and Severe Chronic Kidney Disease (CKD) Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report:

• The report covers the descriptive overview of Moderate and Severe Chronic Kidney Disease (CKD), explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
• Comprehensive insight has been provided into the Moderate and Severe Chronic Kidney Disease (CKD) epidemiology and treatment in the 7MM
• Additionally, an all-inclusive account of both the current and emerging therapies for Moderate and Severe Chronic Kidney Disease (CKD) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
• A detailed review of Moderate and Severe Chronic Kidney Disease (CKD) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Moderate and Severe Chronic Kidney Disease (CKD) market

Report Highlights:

• In the coming years, Moderate and Severe Chronic Kidney Disease (CKD) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
• The companies and academics are working to assess challenges and seek opportunities that could influence Moderate and Severe Chronic Kidney Disease (CKD) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
• Major players are involved in developing therapies for Moderate and Severe Chronic Kidney Disease (CKD). Launch of emerging therapies will significantly impact the Moderate and Severe Chronic Kidney Disease (CKD) market
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Moderate and Severe Chronic Kidney Disease (CKD)
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Moderate and Severe Chronic Kidney Disease (CKD) Report Insights

• Patient Population
• Therapeutic Approaches
• Moderate and Severe Chronic Kidney Disease (CKD) Pipeline Analysis
• Moderate and Severe Chronic Kidney Disease (CKD) Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies

Moderate and Severe Chronic Kidney Disease (CKD) Report Key Strengths

• 11 Years Forecast
• 7MM Coverage
• Moderate and Severe Chronic Kidney Disease (CKD) Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Market
• Drugs Uptake

Moderate and Severe Chronic Kidney Disease (CKD) Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• Market Drivers and Barriers

Key Questions:

Market Insights:

• What was the Moderate and Severe Chronic Kidney Disease (CKD) market share (%) distribution in 2020 and how it would look like in 2034?
• What would be the Moderate and Severe Chronic Kidney Disease (CKD) total market size as well as market size by therapies across the 7MM during the forecast period (2024-2034)?
• What are the key findings pertaining to the market across 7MM and which country will have the largest Moderate and Severe Chronic Kidney Disease (CKD) market size during the forecast period (2024-2034)?
• At what CAGR, the Moderate and Severe Chronic Kidney Disease (CKD) market is expected to grow in 7MM during the forecast period (2020-2034)?
• What would be the Moderate and Severe Chronic Kidney Disease (CKD) market outlook across the 7MM during the forecast period (2020-2034)?
• What would be the Moderate and Severe Chronic Kidney Disease (CKD) market growth till 2032, and what will be the resultant market Size in the year 2034?
• How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

• What is the disease risk, burden and unmet needs of the Moderate and Severe Chronic Kidney Disease (CKD)?
• What is the historical Moderate and Severe Chronic Kidney Disease (CKD) patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What would be the forecasted patient pool of Moderate and Severe Chronic Kidney Disease (CKD) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Moderate and Severe Chronic Kidney Disease (CKD)?
• Out of all 7MM countries, which country would have the highest prevalent population of Moderate and Severe Chronic Kidney Disease (CKD) during the forecast period (2020-2034)?
• At what CAGR the population is expected to grow in 7MM during the forecast period (2020-2034)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

• What are the current options for the Moderate and Severe Chronic Kidney Disease (CKD) treatment, along with the approved therapy?
• What are the current treatment guidelines for the treatment of Moderate and Severe Chronic Kidney Disease (CKD) in the USA, Europe, and Japan?
• What are the Moderate and Severe Chronic Kidney Disease (CKD) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
• How many companies are developing therapies for the treatment of Moderate and Severe Chronic Kidney Disease (CKD)?
• How many therapies are developed by each company for Moderate and Severe Chronic Kidney Disease (CKD) treatment?
• How many are emerging therapies in mid-stage, and late stage of development for Moderate and Severe Chronic Kidney Disease (CKD) treatment?
• What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Moderate and Severe Chronic Kidney Disease (CKD) therapies?
• What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Moderate and Severe Chronic Kidney Disease (CKD) and their status?
• What are the key designations that have been granted for the emerging therapies for Moderate and Severe Chronic Kidney Disease (CKD)?
• What are the global historical and forecasted market of Moderate and Severe Chronic Kidney Disease (CKD)?

Reasons to buy:

• The report will help in developing business strategies by understanding trends shaping and driving the Moderate and Severe Chronic Kidney Disease (CKD) market
• To understand the future market competition in the Moderate and Severe Chronic Kidney Disease (CKD) market and Insightful review of the key market drivers and barriers
• Organize sales and marketing efforts by identifying the best opportunities for Moderate and Severe Chronic Kidney Disease (CKD) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
• Organize sales and marketing efforts by identifying the best opportunities for Moderate and Severe Chronic Kidney Disease (CKD) market
• To understand the future market competition in the Moderate and Severe Chronic Kidney Disease (CKD) market

Table of Contents

1. Key Insights

2. Executive Summary of Moderate and Severe Chronic Kidney Disease (CKD)

3. Competitive Intelligence Analysis for Moderate and Severe Chronic Kidney Disease (CKD)

4. Moderate and Severe Chronic Kidney Disease (CKD): Market Overview at a Glance

• 4.1. Moderate and Severe Chronic Kidney Disease (CKD) Total Market Share (%) Distribution in 2020
• 4.2. Moderate and Severe Chronic Kidney Disease (CKD) Total Market Share (%) Distribution in 2034

5. Moderate and Severe Chronic Kidney Disease (CKD): Disease Background and Overview

• 5.1. Introduction
• 5.2. Sign and Symptoms
• 5.3. Pathophysiology
• 5.4. Risk Factors
• 5.5. Diagnosis

6. Patient Journey

7. Moderate and Severe Chronic Kidney Disease (CKD) Epidemiology and Patient Population

• 7.1. Epidemiology Key Findings
• 7.2. Assumptions and Rationale: 7MM
• 7.3. Epidemiology Scenario: 7MM
  • 7.3.1. Moderate and Severe Chronic Kidney Disease (CKD) Epidemiology Scenario in the 7MM (2020-2034)
• 7.4. United States Epidemiology
  • 7.4.1. Moderate and Severe Chronic Kidney Disease (CKD) Epidemiology Scenario in the United States (2020-2034)
• 7.5. EU-5 Country-wise Epidemiology
  • 7.5.1. Germany Epidemiology
    • 7.5.1.1. Moderate and Severe Chronic Kidney Disease (CKD) Epidemiology Scenario in Germany (2020-2034)
  • 7.5.2. France Epidemiology
    • 7.5.2.1. Moderate and Severe Chronic Kidney Disease (CKD) Epidemiology Scenario in France (2020-2034)
  • 7.5.3. Italy Epidemiology
    • 7.5.3.1. Moderate and Severe Chronic Kidney Disease (CKD) Epidemiology Scenario in Italy (2020-2034)
  • 7.5.4. Spain Epidemiology
    • 7.5.4.1. Moderate and Severe Chronic Kidney Disease (CKD) Epidemiology Scenario in Spain (2020-2034)
  • 7.5.5. United Kingdom Epidemiology
    • 7.5.5.1. Moderate and Severe Chronic Kidney Disease (CKD) Epidemiology Scenario in the United Kingdom (2020-2034)
  • 7.5.6. Japan Epidemiology
    • 7.5.6.1. Moderate and Severe Chronic Kidney Disease (CKD) Epidemiology Scenario in Japan (2020-2034)

8. Treatment Algorithm, Current Treatment, and Medical Practices

• 8.1. Moderate and Severe Chronic Kidney Disease (CKD) Treatment and Management
• 8.2. Moderate and Severe Chronic Kidney Disease (CKD) Treatment Algorithm

9. Unmet Needs

10. Key Endpoints of Moderate and Severe Chronic Kidney Disease (CKD) Treatment

11. Marketed Products

• 11.1. List of Marketed Products in the 7MM
• 11.2. Drug Name: Company Name
  • 11.2.1. Product Description
  • 11.2.2. Regulatory Milestones
  • 11.2.3. Other Developmental Activities
  • 11.2.4. Pivotal Clinical Trials
  • 11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Emerging Therapies

• 12.1. Key Cross
• 12.2. Drug Name: Company Name
  • 12.2.1. Product Description
  • 12.2.2. Other Developmental Activities
  • 12.2.3. Clinical Development
  • 12.2.4. Safety and Efficacy
  • 12.2.5. Product Profile

List to be continued in report

13. Moderate and Severe Chronic Kidney Disease (CKD): Seven Major Market Analysis

• 13.1. Key Findings
• 13.2. Moderate and Severe Chronic Kidney Disease (CKD) Market Size in 7MM
• 13.3. Moderate and Severe Chronic Kidney Disease (CKD) Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

• 15.1. United States: Market Size
  • 15.1.1. Moderate and Severe Chronic Kidney Disease (CKD) Total Market Size in the United States
  • 15.1.2. Moderate and Severe Chronic Kidney Disease (CKD) Market Size by Therapies in the United States
• 15.2. EU-5 countries: Market Size and Outlook
• 15.3. Germany Market Size
  • 15.3.1. Moderate and Severe Chronic Kidney Disease (CKD) Total Market Size in Germany
  • 15.3.2. Moderate and Severe Chronic Kidney Disease (CKD) Market Size by Therapies in Germany
• 15.4. France Market Size
  • 15.4.1. Moderate and Severe Chronic Kidney Disease (CKD) Total Market Size in France
  • 15.4.2. Moderate and Severe Chronic Kidney Disease (CKD) Market Size by Therapies in France
• 15.5. Italy Market Size
  • 15.5.1. Moderate and Severe Chronic Kidney Disease (CKD) Total Market Size in Italy
  • 15.5.2. Moderate and Severe Chronic Kidney Disease (CKD) Market Size by Therapies in Italy
• 15.6. Spain Market Size
  • 15.6.1. Moderate and Severe Chronic Kidney Disease (CKD) Total Market Size in Spain
  • 15.6.2. Moderate and Severe Chronic Kidney Disease (CKD) Market Size by Therapies in Spain
• 15.7. United Kingdom Market Size
  • 15.7.1. Moderate and Severe Chronic Kidney Disease (CKD) Total Market Size in the United Kingdom
  • 15.7.2. Moderate and Severe Chronic Kidney Disease (CKD) Market Size by Therapies in the United Kingdom
• 15.8. Japan Market Outlook
  • 15.8.1. Japan Market Size
  • 15.8.2. Moderate and Severe Chronic Kidney Disease (CKD) Total Market Size in Japan
  • 15.8.3. Moderate and Severe Chronic Kidney Disease (CKD) Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Moderate and Severe Chronic Kidney Disease (CKD)

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

• 20.1. Bibliography
• 20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

The table of contents is not exhaustive; the final content may vary.